Hoffmann-La Roche — Clinical Trial Pipeline

Hoffmann-La Roche has 20 registered trials in the index.

Trials (20)

• A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma Phase 1 · Hoffmann-La Roche
• A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma Phase 2 · Hoffmann-La Roche
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors Phase 2 · Hoffmann-La Roche
• A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer. Phase 2 · Hoffmann-La Roche
• A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors Phase 1 · Hoffmann-La Roche
• A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors. Phase 1 · Hoffmann-La Roche
• A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) Phase 1/2 · Hoffmann-La Roche
• An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants N/A · Hoffmann-La Roche
• A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer. Phase 2 · Hoffmann-La Roche
• A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Phase 3 · Hoffmann-La Roche
• BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer Phase 3 · Hoffmann-La Roche
• A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas Phase 1 · Hoffmann-La Roche
• A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN) Phase 2 · Hoffmann-La Roche
• A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Phase 3 · Hoffmann-La Roche
• A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer Phase 3 · Hoffmann-La Roche
• GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma Phase 2 · Hoffmann-La Roche
• A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors. Phase 1 · Hoffmann-La Roche
• A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors Phase 2 · Hoffmann-La Roche
• A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Phase 3 · Hoffmann-La Roche
• A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer Phase 1 · Hoffmann-La Roche

Related landscapes

• Breast Cancer
• Neoplasms
• Malignant Melanoma, Neoplasms
• Multiple Myeloma
• Ovarian Cancer

Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.